Seroquel;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 32 價格從美金2000起跳。
本報告提供精神分裂症治療藥物的 Seroquel 的平台分析及市場預測，市場特徵為首，評估分析競爭，開發平台等，未來市場競爭等資訊，為您概述為以下內容。
1 目錄 1 目錄 2 簡介
- 2.1 精神分裂症
- 2.2 症狀
- 2.3 精神分裂症 市場
- 2.4 免疫學
- 2.5 病因論
- 2.5.1 遺傳的因素
- 2.5.2 環境的因素
- 2.5.3 腦結構的異常
- 2.6 GlobalData 報告指南
3 精神分裂症: 市場特性
- 3.1 精神分裂症 市場
- 3.2 精神分裂症 市場 預測及年複合成長率
- 3.3 推動力; 精神分裂症 治療藥物市場
- 3.3.1 專利期間的結束; 上市藥物
- 3.3.2 患者群的增加
- 3.3.3 高處方率
- 3.3.4 低的患者的藥物服用遵守率
- 3.3.5 高未飽和需求
4 分類; 精神分裂症
- 4.1 發病年齡 精神分裂症
- 4.1.1 兒童 / 青年時期 / 幼年期 精神分裂症
- 4.1.2 大人的精神分裂症
- 4.2 相關症狀
- 4.2.1 妄想型精神分裂症
- 4.2.2 錯亂型精神分裂症
- 4.2.3 緊張型精神分裂症
- 4.2.4 殘餘型精神分裂症
- 4.2.5 未分類症狀疾患
5 治療方法; 精神分裂症
- 5.1 危機解決團隊 (CRT)
- 5.2 自願及強制的逗留
- 5.3 抗精神病藥
- 5.3.1 典型抗精神病藥物
- 5.3.2 A典型抗精神病藥物
- 5.3.3 死亡率的增加 - 患有癡呆症相關的精神病的高齡患者
6 Seroquel
- 6.1 簡介
- 6.2 作用機制
- 6.3 臨床研究
- 6.3.1 對之前治療非典型抗精神病藥物耐藥性不滿意的患者的Seroquel的有效性及耐藥性評估(第三階段研究)
- 6.3.2 CATIE檢驗; 精神分裂症臨床實驗
- 6.4 銷售額的影響因素;Seroquel
- 6.4.1 專利期間的結束; Seroquel 以及其他的競爭藥物
- 6.4.2 安全性顯示的變化;Seroquel
- 6.4.3 CATIE 檢驗結果
- 6.4.4 患者群的增加
- 6.5 醫藥品評估
- 6.5.1 藥物的風險·效益評估
- 6.5.2 競爭的激烈程度
- 6.6 銷售額預測
- 6.6.1 目標患者群; Seroquel
- 6.6.2 投藥
- 6.6.3 市場滲透率
- 6.6.4 治療的年度成本
- 6.6.5 銷售額預測; Seroquel
7 精神分裂症 市場: 附錄
- 7.1 市場定義
- 7.2 簡稱
- 7.3 調查方法
- 7.4 治療藥物的銷售額預期模式
- 7.5 諮詢方式
- 7.6 免責聲明
- 7.7 資訊來源
1.1 表格一覽
- 表格 1: CATIE 精神分裂症 臨床實驗結果
- 表格 2: 藥物的風險·效益評估; Seroquel
- 表格 3: 競爭;Seroquel
- 表格 4: Seroquel, 年度治療費用; 精神分裂症, 全球
- 表格 5: Seroquel, 精神分裂症, 全球市場, 銷售額預期 ($m)
- 表格 6: Seroquel, 精神分裂症, 全球市場, 銷售額預期 ($m)
- 表格 7: Seroquel, 精神分裂症, 美國, 銷售額預期 ($m)
- 表格 8: Seroquel, 精神分裂症, 美國, 銷售額預測 ($m)
- 表格 9: Seroquel, 精神分裂症, 英國, 銷售額預期 ($m)
- 表格 10: Seroquel, 精神分裂症, 英國, 銷售額預測 ($m)
- 表格 11: Seroquel, 精神分裂症, 法國, 銷售額預期 ($m)
- 表格 12: Seroquel, 精神分裂症, 法國, 銷售額預測 ($m)
- 表格 13: Seroquel, 精神分裂症, 德國, 銷售額預期 ($m)
- 表格 14: Seroquel, 精神分裂症, 德國, 銷售額預測 ($m)
- 表格 15: Seroquel, 精神分裂症, 義大利, 銷售額預期 ($m)
- 表格 16: Seroquel, 精神分裂症, 義大利, 銷售額預測 ($m)
- 表格 17: Seroquel, 精神分裂症, 西班牙, 銷售額預期 ($m)
- 表格 18: Seroquel, 精神分裂症, 西班牙, 銷售額預測 ($m)
- 表格 19: Seroquel, 精神分裂症, 日本, 銷售額預期 ($m)
- 表格 20: Seroquel, 精神分裂症, 日本, 銷售額預測 ($m)
1.2 圖表一覽
- 圖 1: 風險發展; 精神分裂症
- 圖 2: 發展的環境因素; 精神分裂症
- 圖 3: 精神分裂症, 全球市場, 市場 規模 預測 ($bn)
- 圖 4: 分類; 精神分裂症 (發病年齡為基礎)
- 圖 5: PANSS 評分低;典型抗精神病藥物
- 圖 6: 藥物模式圖; Seroquel
- 圖 7: Seroquel, 精神分裂症, 全球市場, 銷售額預期($m)
- 圖 8: Seroquel, 精神分裂症, 美國, 銷售額預期($m)
- 圖 9: Seroquel, 精神分裂症, 英國, 銷售額預期($m)
- 圖 10: Seroquel, 精神分裂症, 法國, 銷售額預期($m)
- 圖 11: Seroquel, 精神分裂症, 德國, 銷售額預期($m)
- 圖 12: Seroquel, 精神分裂症, 義大利, 銷售額預期($m)
- 圖 13: Seroquel, 精神分裂症, 西班牙, 銷售額預期($m)
- 圖 14: Seroquel, 精神分裂症, 日本, 銷售額預期($m)
- 圖 15: Seroquel, 精神分裂症, 全球市場, 銷售額分佈 (%)
Abstract
Summary
GlobalData's pharmaceuticals report, "Seroquel - Analysis and Estimates from 2002 to 2020" provides Seroquel sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Seroquel including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Seroquel including efficacy, safety, pricing and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Seroquel in each of the seven major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents
1. Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Schizophrenia
- 2.2 Symptoms
- 2.3 Schizophrenia Market
- 2.4 Epidemiology
- 2.5 Etiology
- 2.5.1 Genetic Factors
- 2.5.2 Environmental Factors
- 2.5.3 Abnormal Brain Structure
- 2.6 GlobalData Report Guidance
3. Schizophrenia: Market Characterization
- 3.1 Schizophrenia Market
- 3.2 Schizophrenia Market Forecasts and CAGR
- 3.3 Drivers of Schizophrenia Therapeutics Market
- 3.3.1 Patent Expiry of Leading Marketed Drugs
- 3.3.2 Increasing Patient Pool
- 3.3.3 High Prescription Rates
- 3.3.4 Low Patient Compliance Rate
- 3.3.5 High Unmet Need
4. Classification of Schizophrenia
- 4.1 Age of Onset of Schizophrenia
- 4.1.1 Pediatric / Adolescent / Childhood Schizophrenia
- 4.1.2 Adult Schizophrenia
- 4.2 Associated Symptoms
- 4.2.1 Paranoid Schizophrenia
- 4.2.2 Disorganized Schizophrenia
- 4.2.3 Catatonic Schizophrenia
- 4.2.4 Residual Schizophrenia
- 4.2.5 Undifferentiated Disorder
5. Treatment for Schizophrenia
- 5.1 Crisis Resolution Teams (CRT)
- 5.2 Voluntary and Compulsory Detention
- 5.3 Antipsychotics
- 5.3.1 Typical Antipsychotics
- 5.3.2 Atypical Antipsychotics
- 5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
6. Seroquel
- 6.1 Introduction
- 6.2 Mechanism of Action
- 6.3 Clinical Studies
- 6.3.1 Phase III Study Assessing Efficacy and Tolerability of Seroquel in Patients who Experienced an Inadequate Response to or Intolerance to their Prior Antipsychotic Treatment
- 6.3.2 Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Schizophrenia Trial
- 6.4 Factors Affecting Sales of Seroquel
- 6.4.1 Patent Expiry of Seroquel and Other Competing Drugs
- 6.4.2 Safety Labeling Changes of Seroquel
- 6.4.3 CATIE Study Results
- 6.4.4 Increasing Patient Pool
- 6.5 Drug Evaluation
- 6.5.1 Drug Risk Benefit Score
- 6.5.2 Intensity of Competition
- 6.6 Sales Forecasts
- 6.6.1 Target Patient Pool of Seroquel
- 6.6.2 Dosing
- 6.6.3 Market Penetration
- 6.6.4 Annual Cost of Therapy
- 6.6.5 Sales Projections of Seroquel
7. Schizophrenia Market: Appendix
- 7.1 Market Definitions
- 7.2 Abbreviations
- 7.3 Research Methodology
- 7.4 Drug Sales Estimates Model
- 7.5 Contact Us
- 7.6 Disclaimer
- 7.7 Sources
List of Tables
- Table 1: CATIE Schizophrenia Trial Results
- Table 2: Drug Risk Benefit Score of Seroquel
- Table 3: Competitors of Seroquel
- Table 4: Seroquel, Annual Treatment Costs for Schizophrenia, Global, 2010
- Table 5: Seroquel, Schizophrenia, Global, Sales Estimates ($m), 2002-2010
- Table 6: Seroquel, Schizophrenia, Global, Sales Estimates ($m), 2002-2010
- Table 7: Seroquel, Schizophrenia, The US, Sales Estimates ($m), 2002-2010
- Table 8: Seroquel, Schizophrenia, The US, Sales Forecasts ($m), 2011-2016
- Table 9: Seroquel, Schizophrenia, The UK, Sales Estimates ($m), 2002-2010
- Table 10: Seroquel, Schizophrenia, The UK, Sales Forecasts ($m), 2011-2016
- Table 11: Seroquel, Schizophrenia, France, Sales Estimates ($m), 2002-2010
- Table 12: Seroquel, Schizophrenia, France, Sales Forecasts ($m), 2011-2016
- Table 13: Seroquel, Schizophrenia, Germany, Sales Estimates ($m), 2002-2010
- Table 14: Seroquel, Schizophrenia, Germany, Sales Forecasts ($m), 2011-2016
- Table 15: Seroquel, Schizophrenia, Italy, Sales Estimates ($m), 2002-2010
- Table 16: Seroquel, Schizophrenia, Italy, Sales Forecasts ($m), 2011-2016
- Table 17: Seroquel, Schizophrenia, Spain, Sales Estimates ($m), 2002-2010
- Table 18: Seroquel, Schizophrenia, Spain, Sales Forecasts ($m), 2011-2016
- Table 19: Seroquel, Schizophrenia, Japan, Sales Estimates ($m), 2002-2010
- Table 20: Seroquel, Schizophrenia, Japan, Sales Forecasts ($m), 2011-2016
List of Figures
- Figure 1: Risk of Developing Schizophrenia
- Figure 2: Environmental Factors in the Development of Schizophrenia
- Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 2010-2020
- Figure 4: Classification of Schizophrenia based on the Age of Disease Onset
- Figure 5: Reduction in PANSS Scores for Atypical Antipsychotics
- Figure 6: Drug Model Diagram of Seroquel
- Figure 7: Seroquel, Schizophrenia, Global, Sales Estimates($m), 2002-2016
- Figure 8: Seroquel, Schizophrenia, The US, Sales Estimates($m), 2002-2016
- Figure 9: Seroquel, Schizophrenia, The UK, Sales Estimates($m), 2002-2016
- Figure 10: Seroquel, Schizophrenia, France, Sales Estimates($m), 2002-2016
- Figure 11: Seroquel, Schizophrenia, Germany, Sales Estimates($m), 2002-2016
- Figure 12: Seroquel, Schizophrenia, Italy, Sales Estimates($m), 2002-2016
- Figure 13: Seroquel, Schizophrenia, Spain, Sales Estimates($m), 2002-2016
- Figure 14: Seroquel, Schizophrenia, Japan, Sales Estimates($m), 2002-2016
- Figure 15: Seroquel, Schizophrenia, Global, Sales Distribution (%), 2011
|
